Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2016-11-21 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
独立董事候选人声明（韩文君）
Board/Management Information Classification · 95% confidence The document is a formal declaration by an independent director candidate of Shenzhen Xinlitai Pharmaceutical Co., Ltd. It contains detailed statements about the candidate's qualifications, independence, compliance with relevant laws and regulations, and absence of conflicts of interest. There are no financial statements, earnings data, or management discussion of financial results. The document is not an announcement of voting results or a proxy solicitation but a personal declaration related to board membership qualifications. This type of document fits best under Board/Management Information (MANG), as it relates to board member candidacy and qualifications.
2016-11-21 Chinese
独立董事提名人声明（一）
Board/Management Information Classification · 95% confidence The document is a formal public statement from the board of Shenzhen Salubris Pharmaceuticals Co., Ltd. nominating an independent director candidate. It contains detailed declarations about the nominee's qualifications, compliance with regulatory requirements, and independence criteria. There are no financial statements, earnings data, or report summaries. The content is focused on board/management information, specifically the nomination of a board member. This fits the category of Board/Management Information (MANG). The document length is about 4852 characters, which is sufficient for a detailed nomination statement rather than a brief announcement. Therefore, the classification is MANG with high confidence.
2016-11-21 Chinese
独立董事候选人声明（何素英）
Board/Management Information Classification · 95% confidence The document is a detailed declaration by an independent director candidate of Shenzhen Xinlitai Pharmaceutical Co., Ltd. It contains statements about the candidate's qualifications, independence, compliance with relevant laws and regulations, and absence of conflicts of interest. There are no financial statements, earnings data, or report summaries. The content is focused on the candidate's eligibility and compliance for a board position, which aligns with announcements related to board or management changes. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is about 4839 characters, which is sufficient for a detailed declaration rather than a brief announcement or certification.
2016-11-21 Chinese
独立董事关于公司有关事项所发表的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from independent directors regarding nominations for the company's fourth board of directors, including non-independent and independent director candidates, and the independent directors' remuneration plan. It references compliance with company law, stock exchange listing rules, and company articles of association. The content focuses on governance matters, director qualifications, nomination procedures, and remuneration approval. There are no financial statements, earnings data, or audit information. The document is not a report of a meeting or voting results but a formal governance-related opinion. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to changes or nominations in the company's board or senior management.
2016-11-21 Chinese
独立董事候选人声明（王红欣）
Board/Management Information Classification · 95% confidence The document is a detailed declaration by an independent director candidate of Shenzhen Xinlitai Pharmaceutical Co., Ltd. It contains statements about the candidate's qualifications, independence, compliance with relevant laws and regulations, and disclosures required by the Shenzhen Stock Exchange and China Securities Regulatory Commission. There are no financial statements, earnings data, or management discussion of financial results. The content is focused on governance and compliance related to board membership qualifications. This type of document fits best under Board/Management Information (MANG), as it relates to announcements about board members and their qualifications rather than financial reports or other filings.
2016-11-21 Chinese
独立董事提名人声明（三）
Board/Management Information Classification · 95% confidence The document is a formal public statement from the board of Shenzhen Xinlitai Pharmaceutical Co., Ltd. nominating an independent director candidate. It contains detailed declarations about the nominee's qualifications, compliance with regulatory requirements, and independence criteria. There are no financial statements, earnings data, or report attachments. The content is focused on board/management information, specifically the nomination of a board member. Therefore, the document fits the category of Board/Management Information (MANG). The document length is about 4784 characters, which is sufficient for a detailed nomination statement rather than a brief announcement or certification.
2016-11-21 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.